The use of faecal immunochemical testing (FIT) for colorectal cancer screening is associated with a 33% reduction in the risk of death from colorectal cancer, a study claims. The research, published in JAMA Network Open, analysed data from more than 10,000 people aged 52-85 in the US.
Isabel Portillo - prueba fecal cáncer colon EN
Isabel Portillo
Coordinator of Colorectal and prenatal cancer screening at the Basque Health Service-Osakidetza, researcher in the Cancer Biomarkers group at the Biobizkaia Health Research Institute and secretary of the Board of Directors of the Spanish Society of Epidemiology
The study answers the research question and the methods are appropriate. It is in line with the scientific evidence available on this test and the studies that have been carried out, although there are still few controlled clinical trials available. This study corresponds to the designed cohorts and provides a large sample, in line with simulations with a high degree of reliability (MISCAN-colon).
Limitations are clearly specified in the study.
The use of FIT in screening seems to be consistent in terms of acceptability, although the causes of inequalities should be investigated further.
"I have none. I do not receive any funding and I do not work on this article, nor do I have any relationship with the authors’.
- Research article
- Peer reviewed
- People
Chyke A. Doubeni et al.
- Research article
- Peer reviewed
- People
